Detalhe da pesquisa
1.
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
BJU Int
; 127(4): 435-444, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32969563
2.
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Cancer
; 124(11): 2337-2346, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29579325
3.
First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report.
Front Oncol
; 13: 1126476, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36937405
4.
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33664086
5.
Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.
Clin Cancer Res
; 27(2): 429-437, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33023952
6.
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
J Immunother Cancer
; 6(1): 141, 2018 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514390